HEALTHPEAK PROPERTIES, INC.
No enriched coverage for $DOC in the last 7 days.
No SEC Form 4 filings for $DOC in the last 30 days.
See all $DOC insider activity →Wells Fargo maintained an Equal-Weight rating on Healthpeak Properties (DOC) but lowered its price target to $19.00 from $22.00, citing a cautious market outlook. The stock is currently trading at $18.53, with a GF Value™ of $20.35, suggesting it is 8.9% undervalued. Healthpeak has a GF Score™ of 82/100, indicating strong overall performance but with concerns about financial strength.
Wells Fargo reduced its price target for Healthpeak Properties from $22 to $19. The stock is currently trading at $18.82, down 0.84% on the day but up 18.03% year-to-date. Barclays also recently lowered its target to $21 from $24.
Crown Castle (CCI) and Healthpeak Properties (PEAK) both raised 2026 outlooks in Q2. CCI yields 5.4% with a 93% AFFO payout ratio for 2026, while PEAK yields 6.7% with a 78% ratio. CCI trades at 16x forward AFFO, PEAK at 12x. Both have cut dividends previously. CCI's Q2 AFFO rose to $1.13/share, with full-year outlook at $4.53-$4.65.
Recent DOC coverage spans financial news, earnings and market movers.
Analyst price target cut suggests potential downside pressure on the stock.
Wells Fargo reduced its price target for Healthpeak Properties from $22 to $19. The stock is currently trading at $18.82, down 0.84% on the day but up 18.03% year-to-date. Barclays also recently lowered its target to $21 from $24.
The article highlights Healthpeak's higher payout ratio and thinner interest coverage, suggesting limited upside.
Strong payout ratio and raised guidance support a bullish view for the REIT.
Guidance sets a floor for dividend sustainability; any miss could pressure the stock.
AlphAI scores every news story that mentions DOC with an AI model for sentiment and relevance, and aggregates insider trades from HEALTHPEAK PROPERTIES, INC.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Wells Fargo maintained an Equal-Weight rating on Healthpeak Properties (DOC) but lowered its price target to $19.00 from $22.00, citing a cautious market outlook. The stock is currently trading at $18.53, with a GF Value™ of $20.35, suggesting it is 8.9% undervalued. Healthpeak has a GF Score™ of 82/100, indicating strong overall performance but with concerns about financial strength.
1 min readWells Fargo reduced its price target for Healthpeak Properties from $22 to $19. The stock is currently trading at $18.82, down 0.84% on the day but up 18.03% year-to-date. Barclays also recently lowered its target to $21 from $24.
1 min readCrown Castle (CCI) and Healthpeak Properties (PEAK) both raised 2026 outlooks in Q2. CCI yields 5.4% with a 93% AFFO payout ratio for 2026, while PEAK yields 6.7% with a 78% ratio. CCI trades at 16x forward AFFO, PEAK at 12x. Both have cut dividends previously. CCI's Q2 AFFO rose to $1.13/share, with full-year outlook at $4.53-$4.65.
2 min readOmega Healthcare (OHI) raised its quarterly dividend to $0.68, yielding 6.1%. Healthpeak (DOC) yields 6.7% and trades at 12.2x forward AFFO. OHI's AFFO payout ratio is 91% for fiscal 2025, while DOC's is 72%. OHI has less debt but a thinner dividend cushion. DOC cut its dividend twice since 2016 but has wider coverage now.
2 min readHealthpeak Properties (DOC) declared monthly dividends totaling $1.22004 annually, with a 6.48% yield. Shares fell 8.36% to $18.83. Q2 2026 revenue was $310.67M for outpatient, $216.11M for lab, and senior housing showed growth. FFO guidance is $1.73-$1.77, covering the dividend. Asset sales and recapitalizations raised $1.75B. Peers Welltower (WELL) and Ventas (VTR) raised dividends. DOC's payout ratio is 69.7% at midpoint. Interest expenses rose to $92.3M.
2 min readHealthpeak Properties (DOC) declared a monthly dividend of $0.10167 per share for Q4 2026, equating to an annualized dividend of $1.22 per share. This maintains the company's regular monthly dividend schedule.
1 min readHealthpeak Properties (DOC), an S&P 500 healthcare REIT, pays a monthly dividend of $0.10 per share, yielding 6%. The stock has risen 27.5% in 2026, with strong Q1 and Q2 earnings. Management raised FFO guidance to $1.73-$1.77 per share. Analysts' average price target is $23. Rising interest rates pose a risk to REITs.
2 min readHealthpeak Properties (DOC) raised its 2026 guidance, citing strong performance in outpatient medical and lab leasing, and significant growth at its senior housing operator, Janus Living (JAN). The company reported $0.46 FFO per share, flat year-over-year, and used asset sales to reduce debt and fund buybacks. Lab segment NOI declined, and leverage remains at 4.7x EBITDAre.
3 min readDO & CO reported Q1 FY26/27 results despite Middle East headwinds. Sales rose 5% to €642m and EBIT rose 8% to €57m, margin 8.8%. Net profit increased 16% to €31m. Management said conflict-related costs reduced sales by about €40m. FY26/27 targets are 6-8% sales growth with EBIT margin 8.6-9.0%.
4 min readHealthpeak Properties (NYSE:DOC) highlighted Q2 results and updates on capital recycling and leasing. It recapitalized a Brookfield outpatient portfolio, retaining 51% interest and raising $1B cash, and noted a 5.9% trailing cash cap rate. Lab occupancy rose to 78.5%. Net debt/adj. EBITDA was 4.7x with $4.1B liquidity; it repaid $900M debt and repurchased $100M shares.
6 min read
